Multiple Sclerosis (Adult Master Topic)

1. Overview

Multiple Sclerosis (MS) is a chronic, immune-mediated, inflammatory demyelinating disease of the Central Nervous System (CNS). It is characterized by pathological episodes of neurological dysfunction disseminated in time (DIT) and space (DIS), resulting from an autoimmune attack on the myelin sheaths of neurons in the brain, spinal cord, and optic nerves. [1]

The clinical significance of MS is profound: it is the leading cause of non-traumatic neurological disability in young adults, affecting approximately 2.8 million people worldwide. The average age of onset is 20-40 years, with a peak incidence in the third decade of life. [2]

While historically considered a predominantly white-matter disease, modern neuropathology has revealed extensive grey-matter involvement and neurodegeneration from the earliest stages. Advanced imaging studies using 7T MRI and positron emission tomography (PET) have demonstrated cortical demyelination, microglial activation, and meningeal inflammation that correlate with cognitive impairment and long-term disability. [3,4]

Paradigm Shift in Management

Management has been revolutionized by the "Highly Effective Therapy (HET) First" paradigm. The 2024 consensus standards prioritize early initiation of high-potency disease-modifying therapies (DMTs) such as B-cell depleting agents (Ocrelizumab, Ofatumumab) or integrin blockers (Natalizumab) to achieve the goal of NEDA (No Evidence of Disease Activity). [5,6]

This represents a fundamental shift from the traditional "escalation therapy" approach, which delayed the use of highly effective agents until patients demonstrated inadequate response to first-line therapies—often after irreversible neurological damage had occurred.

---

2. Epidemiology

The Latitude Gradient

MS exhibits a striking geographical distribution with prevalence increasing with distance from the equator:

• High-prevalence zones (> 100 per 100,000): Northern Europe, Canada, Northern United States, Southern Australia, New Zealand
• Medium-prevalence zones (50-100 per 100,000): Southern Europe, Mediterranean basin
• Low-prevalence zones (less than 50 per 100,000): Sub-Saharan Africa, Asia, equatorial regions

The latitude gradient suggests that environmental factors—particularly sunlight exposure and vitamin D synthesis—play a critical role in disease susceptibility. Studies have demonstrated that childhood UV exposure and serum 25-hydroxyvitamin D levels are inversely correlated with MS risk. [7]

The EBV Connection: A Causal Link

A landmark 2022 prospective study of over 10 million US military personnel definitively established that Epstein-Barr virus (EBV) infection is the primary environmental trigger for MS. The study demonstrated:

• EBV seropositivity increased MS risk 32-fold
• MS risk increased only after EBV seroconversion
• No other infectious agent showed comparable association
• The temporal relationship (EBV infection preceding MS by years) supports causality [8]

The mechanism likely involves molecular mimicry between EBV nuclear antigen 1 (EBNA1) and myelin antigens, particularly myelin basic protein (MBP) and α-B-crystallin. EBV-infected B cells may cross-react with CNS antigens, breaking immune tolerance. [9]

The "Female Surge"

MS exhibits a significant female preponderance with a female-to-male ratio of approximately 3:1, which has been increasing over recent decades. This ratio varies by phenotype:

• Relapsing-Remitting MS (RRMS): 3-4:1
• Primary Progressive MS (PPMS): 1.5:1

Hormonal factors, particularly the fluctuation of estrogen and progesterone, modulate the Th1/Th17 inflammatory balance. Pregnancy typically induces remission (especially in the third trimester), while the postpartum period is associated with increased relapse risk. [10]

Genetic Susceptibility

While MS is not a Mendelian genetic disease, genetic factors contribute approximately 30% of disease risk:

• HLA-DRB1*15:01 is the strongest genetic risk factor (odds ratio 3.0)
• Non-HLA genes include IL2RA, IL7R, CD58, TNFRSF1A
• Over 230 genetic variants have been identified through genome-wide association studies (GWAS)
• Concordance rate in monozygotic twins: 25-30%
• Sibling recurrence risk: 2-4% (20-40 times general population) [11]

---

3. Aetiology & Pathophysiology

⚠️ THE 7-STEP MOLECULAR MECHANISM

Exam Detail: #### Step 1: Peripheral Sensitization

Autoreactive T-cells (CD4+ Th1 and Th17) are primed in peripheral lymphoid organs, potentially via molecular mimicry between microbial antigens (particularly EBV EBNA1) and myelin epitopes such as:

• Myelin Basic Protein (MBP)
• Proteolipid Protein (PLP)
• Myelin Oligodendrocyte Glycoprotein (MOG)
• Myelin-Associated Glycoprotein (MAG)

Failure of central and peripheral tolerance mechanisms allows these cells to escape thymic deletion and regulatory T-cell suppression. [12]

Step 2: Blood-Brain Barrier (BBB) Transmigration

Activated T-cells upregulate integrin α4β1 (VLA-4), which binds to vascular cell adhesion molecule-1 (VCAM-1) expressed on inflamed cerebral vascular endothelium. This adhesion cascade involves:

1. Rolling: Selectin-mediated tethering
2. Activation: Chemokine receptor signaling (CCR6, CXCR3)
3. Firm adhesion: α4β1-VCAM-1 binding
4. Transmigration: Diapedesis through endothelial tight junctions

Matrix metalloproteinases (MMPs), particularly MMP-9, degrade the basement membrane, facilitating CNS entry. [13]

Step 3: Intrathecal Reactivation

Within the CNS parenchyma, autoreactive T-cells encounter their cognate antigens presented on MHC class II molecules by:

• Resident microglia
• Infiltrating dendritic cells
• Astrocytes (under inflammatory conditions)

This triggers massive local proliferation and release of pro-inflammatory cytokines:

• IFN-γ (Th1 signature): Activates macrophages, upregulates MHC expression
• IL-17, IL-22 (Th17 signature): Recruits neutrophils, disrupts BBB
• TNF-α: Oligodendrocyte toxicity, BBB disruption
• GM-CSF: Myeloid cell activation and survival [14]

Step 4: B-Cell Orchestration

B-cells play a central role in MS pathogenesis beyond antibody production:

Antibody-Dependent Mechanisms:

• Production of anti-myelin antibodies (targeting MBP, MOG, PLP)
• Complement fixation leading to membrane attack complex (MAC) formation
• Antibody-dependent cellular cytotoxicity (ADCC)

Antibody-Independent Mechanisms:

• Professional antigen presentation to T-cells (more efficient than dendritic cells)
• Pro-inflammatory cytokine secretion (IL-6, TNF-α, lymphotoxin)
• Formation of ectopic lymphoid follicle-like structures in meninges
• Production of oligoclonal bands (OCBs) detectable in CSF [15]

The critical importance of B-cells is demonstrated by the remarkable efficacy of anti-CD20 therapies (Ocrelizumab, Ofatumumab), which deplete B-cells but spare plasma cells and antibody levels.

Step 5: Demyelination

Multiple cytotoxic mechanisms converge to strip myelin from axons:

Complement-Mediated Cytotoxicity:

• MAC formation on oligodendrocyte membranes
• Cell lysis and myelin degradation

Macrophage-Mediated Damage:

• Phagocytosis of opsonized myelin
• Release of reactive oxygen species (ROS) and reactive nitrogen species (RNS)
• Secretion of proteolytic enzymes

Direct T-Cell Cytotoxicity:

• Perforin/granzyme-mediated oligodendrocyte apoptosis
• Fas-FasL interaction triggering death receptor pathway

Excitotoxicity:

• Glutamate release from damaged cells
• NMDA and AMPA receptor overactivation
• Calcium influx and mitochondrial dysfunction [16]

Step 6: Conduction Block and Clinical Manifestations

Loss of myelin sheaths results in:

Electrophysiological Consequences:

• Exposure of voltage-gated potassium channels (normally internodal)
• "Current leak" reducing action potential amplitude
• Slowed or blocked saltatory conduction
• Conduction velocity reduced from 70 m/s to 1-2 m/s (or complete block)

Clinical Manifestations:

• Acute symptoms during active inflammation (relapse)
• Uhthoff's phenomenon (heat sensitivity due to temperature-dependent ion channel kinetics)
• Lhermitte's sign (mechanical sensitivity of demyelinated posterior columns)

Partial Compensation:

• Sodium channel redistribution (particularly Nav1.6)
• Axonal remyelination by oligodendrocyte precursor cells (OPCs)
• Synaptic plasticity and cortical reorganization [17]

Step 7: Neurodegeneration - "The Smoldering Fire"

Chronic inflammation leads to progressive axonal loss and brain atrophy through:

Chronic Active Lesions (Smoldering Plaques):

• Rim of activated microglia at lesion edges
• Ongoing slow expansion over years
• Detectable by paramagnetic rim imaging (susceptibility-weighted MRI)

Mitochondrial Dysfunction:

• Chronic energy failure in demyelinated axons
• Impaired axonal transport
• Accumulation of calcium and sodium
• Axonal swelling and eventual transection

Compartmentalized Inflammation:

• Meningeal lymphoid follicles
• Subpial cortical demyelination
• Sequestered from peripheral immune surveillance
• Relatively resistant to systemic immunotherapy

Oxidative Stress:

• Iron accumulation in oligodendrocytes and microglia
• Lipid peroxidation
• DNA damage and cellular senescence [18,19]

This "smoldering" neurodegeneration explains why disability continues to accumulate even when relapses are suppressed by disease-modifying therapies. It represents the primary therapeutic challenge in progressive MS.

---

4. Clinical Presentation

Phenotypic Classification (2013 Revised Criteria)

4.1 Clinically Isolated Syndrome (CIS)

Definition: First clinical episode suggestive of CNS demyelination but not yet meeting full MS diagnostic criteria.

Clinical Scenarios:

• Isolated optic neuritis
• Isolated brainstem syndrome
• Isolated partial transverse myelitis
• Multifocal presentation involving multiple CNS regions

Conversion Risk to Clinically Definite MS:

• CIS with abnormal MRI (≥1 T2 lesion): 60-80% at 5 years
• CIS with normal MRI: 20% at 5 years
• CIS with oligoclonal bands: 60-90% lifetime risk

Management: Early initiation of DMT reduces conversion risk by approximately 40-50% and delays median time to second attack. [20]

4.2 Relapsing-Remitting MS (RRMS)

Characteristics:

• 85% of MS patients at diagnosis
• Discrete acute or subacute neurological episodes (relapses)
• Complete or partial recovery between relapses
• No disease progression between attacks
• Average relapse rate: 0.5-1.5 per year (untreated)

Relapse Definition:

• New neurological symptom(s) or worsening of existing symptoms
• Duration ≥24 hours
• Absence of fever or infection (pseudorelapse exclusion)
• Separation from previous relapse by ≥30 days

Common Relapse Presentations:

• Optic neuritis (20-30%)
• Brainstem syndromes (20-25%)
• Sensory symptoms (30-40%)
• Motor symptoms (30-40%)
• Cerebellar symptoms (10-15%)
• Sphincter dysfunction (5-10%)

4.3 Secondary Progressive MS (SPMS)

Definition: Initial RRMS course followed by progressive neurological deterioration independent of relapses.

Temporal Evolution:

• Median time from RRMS to SPMS: 15-20 years (untreated)
• With modern DMTs: Conversion rate significantly reduced
• Active SPMS: Ongoing relapses or new MRI lesions
• Non-active SPMS: No relapses or new lesions, but progression continues

Clinical Features:

• Gradual worsening of walking ability
• Progressive spasticity
• Cognitive decline
• Bladder dysfunction progression
• Heat sensitivity worsening

Diagnostic Challenge: Distinguishing active disease from progression is critical for therapeutic decision-making. Serum neurofilament light chain (NfL) levels may help identify ongoing active inflammation. [21]

4.4 Primary Progressive MS (PPMS)

Characteristics:

• 10-15% of MS patients at diagnosis
• Progressive neurological decline from onset
• No distinct relapses
• Slightly older age of onset (mean 40 years vs 30 for RRMS)
• More equal gender distribution (F:M = 1.5:1)

Typical Presentation:

• Progressive myelopathy (weakness, spasticity, ataxia)
• Less frequent cognitive involvement than RRMS
• Less inflammatory activity on MRI (fewer enhancing lesions)
• Slower accumulation of T2 lesion burden but more brain atrophy

Diagnostic Criteria Refinement: 2017 McDonald criteria allow diagnosis with:

• 1 year of disability progression PLUS
• Two of: ≥1 T2 lesion in characteristic location, ≥2 spinal cord lesions, CSF oligoclonal bands

Prognosis: Historically poor, but Ocrelizumab (ORATORIO trial) demonstrated 24% reduction in disability progression. [22]

---

5. Cardinal Clinical Syndromes

5.1 Optic Neuritis (ON)

Epidemiology: Present as initial symptom in 20-30% of MS patients; occurs in 70% at some point during disease course.

Clinical Features:

• Subacute visual loss: Develops over hours to days
• Unilateral (95% of MS-associated ON; bilateral suggests NMOSD or MOGAD)
• Painful eye movements: Retro-orbital or periorbital pain, exacerbated by eye movement (92%)
• Color vision impairment: Red desaturation (subjective dimming of red color)
• Central scotoma: Most common visual field defect
• Relative afferent pupillary defect (RAPD): Marcus Gunn pupil

Ophthalmoscopy:

• Retrobulbar neuritis (66%): Normal-appearing optic disc (inflammation behind globe)
• Papillitis (33%): Optic disc swelling
• Peripapillary retinal nerve fiber layer (RNFL) thinning develops over 3-6 months

Investigation:

• MRI orbits with fat suppression and gadolinium: Enhancement of optic nerve
• MRI brain: Presence of white matter lesions increases MS conversion risk to 50% at 5 years (vs 16% with normal MRI)
• Visual evoked potentials (VEP): Prolonged P100 latency (> 118 ms) indicates demyelination

Management:

• IV methylprednisolone 1g daily × 3 days: Accelerates visual recovery but no effect on final visual acuity
• Oral steroids alone: Previously contraindicated due to Optic Neuritis Treatment Trial (ONTT) showing increased recurrence risk; however, recent data with high-dose oral prednisone (1250 mg) shows equivalence to IV therapy
• Plasma exchange: Reserved for severe steroid-refractory cases
• DMT initiation: Consider in all patients with ON and MRI white matter lesions to reduce MS conversion risk [23,24]

5.2 Transverse Myelitis (TM)

Definition: Spinal cord inflammation causing bilateral (though often asymmetric) motor, sensory, and autonomic dysfunction.

Clinical Features:

• Motor: Weakness (paraplegia or quadriplegia), spasticity, hyperreflexia, extensor plantar responses
• Sensory: Sensory level (band-like tightness), paresthesias, proprioceptive loss
• Autonomic: Bladder dysfunction (urinary retention or incontinence), bowel dysfunction, sexual dysfunction
• Pain: Radicular or back pain in 30-50%

MS-Associated TM Characteristics:

• Partial (not complete) cord syndrome
• Asymmetric symptoms
• Short-segment lesion (less than 3 vertebral segments on MRI)
• Peripheral cord lesion location (dorsolateral or lateral columns)

⚠️ Red Flags for Alternative Diagnoses:

• Longitudinally extensive TM (LETM): ≥3 vertebral segments → Consider NMOSD, MOGAD, sarcoidosis, spinal dural arteriovenous fistula
• Central cord location with massive swelling: Suggests NMOSD
• Complete sensory level with areflexia: Spinal cord infarction
• Bilateral symmetric presentation: Raises suspicion for aquaporin-4 antibody disease

Investigation:

• MRI spine with gadolinium: Essential to characterize lesion length, location, and enhancement
• Brain MRI: Assess for dissemination in space
• CSF analysis: Oligoclonal bands, elevated protein, lymphocytic pleocytosis (typically less than 50 cells/μL)
• Serology: AQP4-IgG (NMOSD), MOG-IgG, HIV, syphilis, B12, copper

Management:

• Acute: High-dose IV methylprednisolone 1g daily × 3-5 days
• Refractory cases: Plasma exchange (5-7 cycles over 10-14 days)
• Rehabilitation: Early intensive physiotherapy, occupational therapy, bladder management [25]

5.3 Brainstem Syndromes

Internuclear Ophthalmoplegia (INO)

Pathognomonic Sign: Lesion of medial longitudinal fasciculus (MLF) in the pons or midbrain.

Clinical Features:

• Failure of adduction of the ipsilateral eye (on the side of MLF lesion)
• Horizontal nystagmus of the contralateral abducting eye
• Preserved convergence (distinguishes from CN III palsy)
• Bilateral INO (BINO): Virtually diagnostic of MS in young patients

Mechanism: Disruption of connection between contralateral CN VI nucleus and ipsilateral CN III nucleus (medial rectus subnucleus).

Example: Left MLF lesion → When patient looks right, left eye fails to adduct, right eye exhibits nystagmus.

Other Brainstem Manifestations

Trigeminal Neuralgia:

• Paroxysmal, lancinating facial pain in trigeminal distribution
• Typically younger age than classical TN (less than 50 years)
• Bilateral in 10-20% (vs less than 5% in classical TN)
• Due to demyelinating plaque at trigeminal root entry zone

Vertigo and Nystagmus:

• Acute vestibular syndrome (mimicking vestibular neuritis)
• Central positional nystagmus (direction-changing, non-fatigable)
• Lesions involving vestibular nuclei or vestibulocerebellar pathways

Facial Nerve Palsy:

• Lower motor neuron pattern (forehead involved)
• Lesion at facial nerve nucleus or intra-axial segment

Dysphagia and Dysarthria:

• Lesions affecting CN IX, X, XII nuclei or corticobulbar tracts
• Pseudobulbar palsy (upper motor neuron): Spastic dysarthria, emotional lability, brisk jaw jerk

5.4 Cerebellar Syndromes

Clinical Features:

• Ataxia: Limb, truncal, or gait ataxia
• Dysmetria: Impaired finger-nose-finger and heel-shin testing
• Intention tremor: Worsens with goal-directed movement
• Dysdiadochokinesia: Impaired rapid alternating movements
• Scanning dysarthria: Irregular speech rhythm (syllabic emphasis)
• Nystagmus: Gaze-evoked or rebound nystagmus

Functional Impact: Cerebellar dysfunction is a major driver of disability and is poorly responsive to current therapies.

Investigation: MRI reveals cerebellar peduncle or hemispheric lesions; cerebellar atrophy correlates with symptom severity.

5.5 Cognitive and Psychiatric Manifestations

Epidemiology: Affects 40-70% of MS patients, often underrecognized.

Cognitive Domains Affected:

• Processing speed: Most commonly and earliest affected
• Working memory: Paced Auditory Serial Addition Test (PASAT)
• Executive function: Planning, problem-solving, cognitive flexibility
• Episodic memory: Verbal and visuospatial memory
• Attention: Sustained and divided attention

Assessment Tools:

• Brief International Cognitive Assessment for MS (BICAMS): 15-minute screening battery
• Symbol Digit Modalities Test (SDMT): Most sensitive single test
• Comprehensive neuropsychological battery for detailed evaluation

Psychiatric Comorbidities:

• Depression: Lifetime prevalence 50%, increases suicide risk (7.5x general population)
• Anxiety disorders: 36% prevalence
• Pseudobulbar affect: Pathological laughing/crying in 10%
• Psychosis: Rare but 2-3x more common than general population

Management:

• Cognitive rehabilitation and compensatory strategies
• Treatment of contributing factors (fatigue, depression, sleep disorders)
• Disease-modifying therapies may stabilize or improve cognition
• Pharmacotherapy: Antidepressants (SSRIs), anxiolytics, consider cognitive enhancers (limited evidence) [26,27]

---

6. Characteristic Phenomena

Lhermitte's Sign

Description: Electric shock-like sensation radiating down the spine and into the limbs triggered by neck flexion.

Mechanism: Mechanical irritation of demyelinated posterior columns (dorsal columns) of the cervical spinal cord during neck flexion stretches the cord.

Specificity: Non-specific for MS; also seen in cervical spondylotic myelopathy, B12 deficiency, radiation myelopathy, atlantoaxial instability.

Uhthoff's Phenomenon

Description: Transient worsening of neurological symptoms with elevation of body temperature.

Triggers:

• Hot weather, hot baths, saunas
• Exercise
• Fever, infection
• Eating hot food or drinks (less common)

Mechanism: Elevated temperature slows conduction velocity in demyelinated axons due to temperature-dependent kinetics of voltage-gated sodium channels. Even 0.5°C increase can block conduction.

Clinical Implications:

• Not a true relapse (resolves with cooling)
• Differentiate from pseudorelapse (symptoms from infection without new CNS inflammation)
• May respond to cooling strategies, air conditioning, cooling vests

Historical Note: First described by Wilhelm Uhthoff in 1890 observing visual symptoms in MS patients after exercise.

Pulfrich Phenomenon

Description: Moving objects appear to travel in elliptical or curved paths rather than straight lines.

Mechanism: Unequal conduction velocities between the two optic nerves cause temporal delay in visual processing, creating perception of depth distortion.

Clinical Scenario: Patient with previous optic neuritis in one eye reports difficulty judging distance of approaching vehicles or perceives pendulum swinging in ellipse rather than straight line.

---

7. Investigations

7.1 Diagnostic Criteria: McDonald Criteria (2017 Revision)

Fundamental Principles: Diagnosis requires demonstration of:

1. Dissemination in Space (DIS): Lesions in multiple CNS locations
2. Dissemination in Time (DIT): Lesions occurring at different time points
3. Exclusion of alternative diagnoses: No better explanation

MRI Criteria for DIS

Requires ≥1 T2-hyperintense lesion in ≥2 of 4 characteristic CNS regions:

1. Periventricular: Adjacent to lateral ventricles (most specific location)
2. Cortical or Juxtacortical: Touching or immediately adjacent to cortex
3. Infratentorial: Brainstem, cerebellum, or cerebellar peduncles
4. Spinal cord: Cervical or thoracic cord

Technical Requirements:

• Exclude lesions in optic nerve from DIS (counted separately)
• Symptomatic lesions can contribute to DIS in CIS
• Gadolinium not required for DIS

MRI Criteria for DIT

Method 1: Simultaneous presence of:

• Gadolinium-enhancing lesions (active inflammation) AND
• Non-enhancing lesions (chronic lesions)

Method 2: New T2-hyperintense or gadolinium-enhancing lesion on follow-up MRI (compared to baseline scan at any interval)

2017 Addition: Presence of CSF-specific oligoclonal bands can substitute for DIT requirement, allowing diagnosis at first presentation if DIS criteria met.

CSF Criteria

Oligoclonal Bands (OCBs):

• ≥2 CSF-specific bands not present in serum (isoelectric focusing with immunofixation)
• Present in > 95% of MS patients
• Can fulfill DIT criterion in 2017 revision
• Persist throughout disease course

Other CSF Findings:

• Mild lymphocytic pleocytosis (less than 50 cells/μL; higher counts suggest alternative diagnoses)
• Mildly elevated protein (typically less than 1 g/L)
• Normal glucose
• Elevated IgG index: (CSF IgG/serum IgG) / (CSF albumin/serum albumin) > 0.7
• Elevated IgG synthesis rate

Special Scenarios

Primary Progressive MS Diagnosis: Requires:

• 1 year of disability progression (retrospective or prospective) PLUS
• Two of the following:
  • ≥1 T2 lesion in periventricular, cortical/juxtacortical, or infratentorial regions
  • ≥2 T2 spinal cord lesions
  • CSF-specific oligoclonal bands

Pediatric MS: Modified criteria account for larger lesions, higher frequency of ADEM-like presentations.

Radiologically Isolated Syndrome (RIS): Incidental MRI findings meeting DIS criteria without clinical symptoms. 30-40% develop clinical MS within 5 years. [1,28]

7.2 Advanced MRI Techniques

Exam Detail: #### Conventional Sequences

T2-FLAIR (Fluid-Attenuated Inversion Recovery):

• Suppresses CSF signal
• Optimal for periventricular lesion detection
• Ovoid lesions perpendicular to ventricles (Dawson's fingers)

T1 Post-Gadolinium:

• Identifies active inflammation (BBB breakdown)
• Enhancement persists 2-6 weeks
• Nodular or ring-enhancing patterns

T1-Weighted (Pre-Contrast):

• Hypointense lesions ("black holes") indicate severe tissue destruction, axonal loss
• Chronic black holes correlate with disability
• Acute black holes may partially resolve

T2-Weighted:

• Hyperintense lesions show total lesion burden
• Poor specificity (inflammation, edema, gliosis, demyelination all appear bright)

Advanced Imaging

Susceptibility-Weighted Imaging (SWI) / Phase Imaging:

• Paramagnetic Rim Lesions (PRL): Chronic active "smoldering" lesions with iron-laden macrophages at edges
• PRL presence predicts faster disability progression
• "Central vein sign": Vein running through center of lesion (90% of MS plaques; helps distinguish from small vessel disease)

Magnetization Transfer Imaging (MTI):

• Quantifies myelin content
• Magnetization transfer ratio (MTR) reduced in demyelination
• Detects abnormalities in normal-appearing white matter (NAWM)

Diffusion Tensor Imaging (DTI):

• Fractional anisotropy (FA) reduced in lesions and NAWM
• Mean diffusivity (MD) increased
• Assesses white matter tract integrity

MR Spectroscopy (MRS):

• N-acetylaspartate (NAA) reduced (neuronal/axonal loss)
• Choline elevated (membrane turnover)
• Lactate present in acute inflammation
• Myo-inositol elevated (glial activation)

Optical Coherence Tomography (OCT):

• Non-invasive retinal imaging
• Measures retinal nerve fiber layer (RNFL) and ganglion cell layer (GCL) thickness
• Correlates with brain atrophy and disability
• Detects subclinical optic nerve involvement [29]

7.3 Evoked Potentials

Visual Evoked Potentials (VEP):

• P100 latency: Normal less than 118 ms
• Prolonged in demyelination (may be > 150 ms)
• Persistent despite clinical recovery from optic neuritis
• Detects subclinical lesions

Somatosensory Evoked Potentials (SSEP):

• Assesses posterior column pathways
• Prolonged latencies or absent responses indicate demyelination
• Median nerve and tibial nerve stimulation

Brainstem Auditory Evoked Potentials (BAEP):

• Less commonly abnormal in MS
• Evaluates auditory pathways through brainstem

Motor Evoked Potentials (MEP):

• Transcranial magnetic stimulation (TMS)
• Central motor conduction time (CMCT) prolonged
• Correlates with motor disability

7.4 Emerging Biomarkers

Serum Neurofilament Light Chain (sNfL):

• Marker of neuroaxonal damage
• Elevated during relapses and disease activity
• Predicts disability progression
• Monitored to assess treatment response
• Measured by single-molecule array (Simoa) assay

Glial Fibrillary Acidic Protein (GFAP):

• Marker of astrocytic activation
• Elevated in progressive MS
• Potential biomarker for smoldering inflammation

Chitinase-3-Like-1 (CHI3L1):

• CSF biomarker associated with disease severity
• Correlates with inflammation and neurodegeneration [30]

---

8. Differential Diagnosis

8.1 Other CNS Demyelinating Diseases

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Key Distinguishing Features:

• Serology: Aquaporin-4 (AQP4) IgG antibodies (70-80% seropositive)
• MRI Brain: Often normal or non-specific; area postrema, hypothalamus, brainstem lesions
• MRI Spine: Longitudinally extensive transverse myelitis (LETM ≥3 vertebral segments), central cord, extensive edema
• Clinical: Bilateral optic neuritis, intractable hiccups/nausea (area postrema syndrome), severe attacks with poor recovery
• CSF: OCBs less common (20-30%)
• Treatment: Rituximab, eculizumab, inebilizumab, satralizumab; MS therapies may worsen NMOSD

MOG Antibody-Associated Disease (MOGAD)

Key Features:

• Serology: Myelin oligodendrocyte glycoprotein (MOG) IgG antibodies (live cell-based assay required)
• Clinical: Bilateral simultaneous or sequential optic neuritis, LETM, ADEM-like presentations, cortical encephalitis
• MRI: Fluffy, ill-defined lesions; optic nerve sheath enhancement; conus medullaris involvement
• Prognosis: Better recovery than NMOSD but relapsing course common
• Treatment: Steroids, IVIG, rituximab or mycophenolate for relapse prevention

8.2 Inflammatory/Infectious

Acute Disseminated Encephalomyelitis (ADEM):

• Monophasic, post-infectious/post-vaccination
• Encephalopathy (altered consciousness)
• Large, poorly demarcated lesions
• Deep grey matter involvement
• Predominantly pediatric

Neurosarcoidosis:

• Cranial neuropathies (especially CN VII)
• Leptomeningeal enhancement (linear, nodular)
• Hypothalamic/pituitary involvement
• Systemic sarcoidosis features (hilar lymphadenopathy, elevated ACE, hypercalcemia)

CNS Vasculitis:

• Stroke-like presentations
• Systemic symptoms (fever, weight loss)
• Elevated inflammatory markers (ESR, CRP)
• Angiography or biopsy for diagnosis

Lyme Neuroborreliosis:

• Endemic area exposure
• CSF pleocytosis (often > 50 cells)
• Lyme serology and CSF Borrelia antibodies
• Cranial neuropathies, radiculopathies

8.3 Genetic/Metabolic

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL):

• NOTCH3 gene mutation
• Family history of stroke, migraine, dementia
• Anterior temporal lobe and external capsule T2 hyperintensities
• No gadolinium enhancement
• Skin biopsy: Granular osmiophilic material in small vessels

Mitochondrial Disorders (e.g., MELAS):

• Maternal inheritance
• Stroke-like episodes, seizures, lactic acidosis
• Cortical lesions not respecting vascular territories
• Elevated lactate on MR spectroscopy

Adrenoleukodystrophy:

• X-linked (males)
• Splenium of corpus callosum involvement
• Adrenal insufficiency
• Very long chain fatty acids (VLCFA) elevated

8.4 Neoplastic

CNS Lymphoma:

• Periventricular lesions
• Mass effect, restricted diffusion
• Homogeneous enhancement
• CSF cytology, brain biopsy
• Association with immunosuppression

Gliomatosis Cerebri:

• Diffuse white matter infiltration
• Mass effect and architectural distortion
• Biopsy for diagnosis

8.5 Mimics in Older Adults

Small Vessel Ischemic Disease:

• Age > 60, vascular risk factors
• Lacunar infarcts in basal ganglia, thalamus
• Confluent periventricular white matter changes
• No enhancement, no optic nerve/spinal cord lesions

Cerebral Amyloid Angiopathy:

• Lobar hemorrhages, cortical superficial siderosis
• Gradient echo (GRE) or SWI shows microbleeds

---

9. Management

9.1 Acute Relapse Management

High-Dose Corticosteroids

First-Line Therapy:

• Methylprednisolone 1000 mg IV daily × 3-5 days (most common regimen)
• Oral prednisone 1250 mg daily × 3-5 days (non-inferior to IV in recent trials)

Mechanism: Suppresses inflammation, restores BBB integrity, reduces edema, promotes apoptosis of activated T-cells.

Evidence: Accelerates recovery from relapses but no long-term effect on disability (ONTT, other trials).

Indications:

• Functionally significant relapse (motor, visual, cerebellar, brainstem)
• Symptoms interfering with activities of daily living
• Not required for pure sensory relapses

Contraindications/Cautions:

• Active infections
• Uncontrolled diabetes, hypertension
• Psychiatric instability
• Peptic ulcer disease

Side Effects:

• Insomnia, mood changes, psychosis
• Hyperglycemia
• Hypertension
• Gastritis
• Avascular necrosis of hip (with repeated courses)

Oral Taper: No evidence that tapering prevents relapse recurrence; short courses without taper are standard.

Plasma Exchange (PLEX)

Indications:

• Severe relapse (e.g., complete paraplegia, bilateral blindness)
• Inadequate response to corticosteroids after 5-7 days
• Corticosteroid contraindications

Protocol:

• 5-7 exchanges over 10-14 days
• 1-1.5 plasma volumes per exchange
• Replacement with albumin ± FFP

Evidence: Moderate to significant improvement in 40-45% of steroid-refractory cases. Earlier initiation (less than 3 months from symptom onset) associated with better outcomes.

Complications: Hypotension, line-related infections, citrate toxicity, coagulopathy. [31]

---

9.2 Disease-Modifying Therapies (DMTs)

The therapeutic landscape has been revolutionized by the shift from escalation therapy (starting with low-efficacy agents) to early highly effective therapy (HET) in appropriate candidates.

9.2.1 High-Efficacy DMTs (First-Line Consideration)

Exam Detail: #### Anti-CD20 B-Cell Depleting Therapies

Ocrelizumab:

• Mechanism: Humanized monoclonal antibody targeting CD20 on B-cells (pre-B cells through mature B-cells, sparing plasma cells)
• Route: IV infusion (600 mg every 6 months; initial split dose: 300 mg × 2 separated by 14 days)
• Efficacy (OPERA I/II for RRMS):
  • 46% reduction in annualized relapse rate (ARR) vs interferon
  • 40% reduction in 3-month confirmed disability progression
  • 95% reduction in gadolinium-enhancing lesions
• Efficacy (ORATORIO for PPMS):
  • 24% reduction in 3-month confirmed disability progression (first therapy proven effective in PPMS)
  • Benefit primarily in younger patients (less than 45 years), with active inflammation
• Monitoring:
  • "Baseline: Hepatitis B serology (HBsAg, anti-HBc, anti-HBs), quantitative immunoglobulins, CBC"
  • "Pre-infusion: CBC"
  • "Annual: Immunoglobulin levels"
• Adverse Effects:
  • Infusion reactions (30-40%, mostly mild; reduced with premedication)
  • Infections (URTIs, UTIs); serious infection risk ~10% vs 8% placebo
  • Hypogammaglobulinemia with repeated dosing
  • Theoretical PML risk (not observed in trials; post-marketing rare cases)
  • "Malignancy: Breast cancer signal (numerically higher, unclear causation)"
• Contraindications: Active hepatitis B infection, severe immunodeficiency

Ofatumumab:

• Mechanism: Fully human anti-CD20 monoclonal antibody (binds different CD20 epitope than Ocrelizumab)
• Route: Subcutaneous injection (20 mg monthly after loading doses)
• Advantages: Self-administered at home, no infusion reactions, reduced healthcare burden
• Efficacy (ASCLEPIOS I/II):
  • 50-58% reduction in ARR vs teriflunomide
  • 34-32% reduction in 3-month confirmed disability progression
  • Superior MRI outcomes
• Monitoring: Similar to Ocrelizumab
• Adverse Effects: Injection site reactions (mild), infection profile similar to Ocrelizumab, systemic reactions rare

Natalizumab (Integrin Blocker)

• Mechanism: Humanized monoclonal antibody against α4-integrin subunit (α4β1 and α4β7), blocks VLA-4/VCAM-1 interaction, prevents T-cell CNS entry
• Route: IV infusion (300 mg every 4 weeks)
• Efficacy (AFFIRM trial):
  • 68% reduction in ARR (one of highest efficacy DMTs)
  • 42% reduction in disability progression
  • 83% reduction in gadolinium-enhancing lesions
• PML Risk - CRITICAL:
  • Caused by JC virus reactivation in CNS
  • "Risk factors:"
    1. JCV antibody positive (essential screening)
    2. Prior immunosuppressant use (e.g., azathioprine, mitoxantrone)
    3. Duration of Natalizumab > 2 years
  • "Stratified Risk:"
    • JCV negative: ~1:10,000
    • JCV positive, no prior immunosuppression, less than 2 years: 1:1,000
    • JCV positive, prior immunosuppression, > 2 years: 1:100
  • "Monitoring: MRI brain every 3-6 months, JCV antibody index every 6 months, vigilance for new symptoms"
  • "PML Presentation: Subacute cognitive decline, motor weakness, aphasia, visual deficits; MRI shows large T2 hyperintense lesions (subcortical U-fibers, no mass effect initially)"
• Extended Interval Dosing: Dosing every 5-6 weeks reduces PML risk while maintaining efficacy
• Washout: Before switching to other DMTs, monitor for rebound activity (case reports of severe relapses) [32,33]

Alemtuzumab (Lymphocyte Depletion)

• Mechanism: Anti-CD52 monoclonal antibody; depletes T and B lymphocytes
• Route: IV infusion (12 mg daily × 5 days, then 12 mg daily × 3 days one year later)
• Efficacy (CARE-MS I/II):
  • 55% reduction in ARR vs interferon
  • Improved disability outcomes
  • Durable responses (many patients require no further treatment courses)
• Serious Autoimmune Adverse Effects (30-40%):
  • "Autoimmune thyroid disease (most common): Graves' disease, hypothyroidism"
  • "Immune thrombocytopenic purpura (ITP): Can be severe/fatal"
  • "Goodpasture's syndrome (anti-glomerular basement membrane disease): Rare but serious"
  • Autoimmune hemolytic anemia
  • Onset typically 2-4 years post-treatment
• Monitoring (Monthly × 48 Months Post-Infusion):
  • CBC with differential
  • Serum creatinine
  • Urinalysis with microscopy
  • Thyroid function tests (TSH)
• Infections: Infusion reactions, herpes reactivation (prophylaxis with acyclovir), listeriosis
• Current Status: Use declined due to autoimmune risks; reserved for highly active disease without safer alternatives [34]

Cladribine (Selective Lymphocyte Depletion)

• Mechanism: Purine nucleoside analog; preferentially depletes lymphocytes (accumulates in cells with high deoxycytidine kinase and low 5'-nucleotidase); oral prodrug
• Route: Oral tablets (short-course regimen)
• Dosing: 3.5 mg/kg cumulative dose over 2 years (divided into treatment weeks at months 0, 1, 12, 13)
• Efficacy (CLARITY trial):
  • 58% reduction in ARR vs placebo
  • 47% reduction in 3-month disability progression
• Advantages:
  • Oral administration
  • Short treatment duration (4-5 treatment weeks total)
  • No continuous therapy required; reconstitution of immune system occurs over 6-12 months
  • "Immune reset" may provide durable benefit
• Adverse Effects:
  • Lymphopenia (expected; nadir at 2-3 months)
  • Infections (herpes zoster reactivation - consider prophylaxis)
  • Malignancy concerns (numerically higher in trials, unclear causation)
• Monitoring:
  • "Baseline: CBC, LFTs, HIV, hepatitis B/C, VZV serology, pregnancy test"
  • "During treatment: CBC, LFTs"
  • "Post-treatment: Monitor lymphocyte count (delay subsequent courses if less than 500/μL)"
• Contraindications: Pregnancy, active chronic infection (HIV, TB, hepatitis), malignancy [35]

9.2.2 Moderate-Efficacy DMTs

Sphingosine-1-Phosphate (S1P) Receptor Modulators:

Fingolimod:

• First oral DMT approved for MS
• Blocks S1P receptors, traps lymphocytes in lymph nodes
• 54% reduction in ARR vs placebo
• Adverse effects: Bradycardia at first dose (requires monitoring), macular edema, PML risk (rare), infections, liver enzyme elevation
• First-dose cardiac monitoring required (6 hours; ECG, pulse, blood pressure)

Siponimod:

• Selective S1P1 and S1P5 modulator
• Approved for SPMS with active disease
• 26% reduction in disability progression (EXPAND trial)
• Requires CYP2C9 genotyping (contraindicated in CYP2C9*3/*3)

Ozanimod, Ponesimod:

• Newer S1P modulators
• Similar efficacy and safety profiles
• Less cardiac effects than fingolimod (selective S1P1/S1P5)

Dimethyl Fumarate (DMF):

• Oral BID dosing
• Mechanism: Nrf2 pathway activation (antioxidant response), NF-κB inhibition
• 53% reduction in ARR vs placebo (DEFINE trial)
• Adverse effects: Flushing (50%), GI upset (diarrhea, nausea, abdominal pain), lymphopenia (monitor CBC), PML risk (rare, associated with prolonged severe lymphopenia less than 500/μL)
• Monitoring: CBC every 3 months

Teriflunomide:

• Oral daily dosing
• Mechanism: Inhibits dihydroorotate dehydrogenase (pyrimidine synthesis)
• 31% reduction in ARR vs placebo
• Adverse effects: Diarrhea, nausea, hair thinning, hepatotoxicity, teratogenic (washout required before pregnancy)
• Monitoring: LFTs monthly × 6 months, then every 3 months; blood pressure

Injectable Platform Therapies (Historically First-Line, Now Less Commonly Used):

Interferon-β (IFN-β) formulations:

• IFN-β-1a IM (Avonex), IFN-β-1a SC (Rebif), IFN-β-1b SC (Betaseron, Extavia)
• Mechanism: Immunomodulatory (Th1/Th2 balance, reduces T-cell proliferation)
• 30% reduction in ARR
• Adverse effects: Flu-like symptoms, injection site reactions, depression, liver enzyme elevation, cytopenias
• Declining use due to availability of more effective oral/infusion therapies with better tolerability

Glatiramer Acetate (GA):

• SC injection (daily 20 mg or three times weekly 40 mg)
• Mechanism: Synthetic amino acid polymer; MHC binding, regulatory T-cell induction
• 29% reduction in ARR
• Adverse effects: Injection site reactions (lipoatrophy), immediate post-injection reaction (flushing, chest tightness, palpitations - benign, self-limiting)
• Favorable safety profile; option in pregnancy (limited data) [36]

9.2.3 DMT Selection Strategy

2024 Consensus Approach:

Factors Favoring Early High-Efficacy Therapy (HET):

• High baseline MRI lesion burden (> 10 T2 lesions)
• Presence of gadolinium-enhancing lesions
• Severe initial presentation (e.g., myelitis with significant disability)
• Frequent relapses (> 2 per year)
• Poor recovery from relapses
• Young age (less than 30 years) with aggressive disease
• Spinal cord involvement
• Infratentorial lesions
• Elevated neurofilament light chain

Patient-Specific Considerations:

• JCV status: If positive with high index, avoid Natalizumab
• Pregnancy planning: Avoid teratogens (teriflunomide), caution with Alemtuzumab (autoimmune thyroid disease complicates pregnancy), consider glatiramer or interferons
• Infection risk: Avoid high-efficacy DMTs in immunocompromised or high infection risk
• Route/convenience: Patient preference for oral (cladribine, fumarate, S1P modulators) vs infusion (Ocrelizumab, Natalizumab) vs injection
• Comorbidities: Cardiac disease (caution with S1P modulators), liver disease (avoid hepatotoxic agents)

Monitoring Disease Activity on DMT:

• Clinical: Relapse frequency, disability progression (EDSS)
• MRI: Annual brain MRI (compare new T2 lesions, gadolinium-enhancing lesions, brain atrophy)
• Biomarkers: Serum neurofilament light chain (sNfL) - rising levels indicate disease activity

Switching DMTs:

• Lack of efficacy: Evidence of Disease Activity (EDA) - clinical relapses, new MRI lesions, disability progression → Escalate to higher-efficacy DMT
• Intolerability: Switch to alternative class
• Washout considerations: Balance risk of disease reactivation vs infection/overlap toxicity (e.g., after Natalizumab or Fingolimod, risk of rebound activity) [6,37]

---

9.3 Symptomatic Management

Spasticity

Non-Pharmacological:

• Physiotherapy, stretching exercises
• Treatment of exacerbating factors (UTI, pressure sores, constipation)

Pharmacological:

• Baclofen: GABA-B agonist; start 5 mg TID, titrate to max 80-100 mg/day; adverse effects include sedation, weakness
• Tizanidine: α2-adrenergic agonist; start 2 mg daily, titrate to max 36 mg/day; adverse effects include sedation, dry mouth, hepatotoxicity (monitor LFTs)
• Dantrolene: Direct muscle relaxant; 25 mg daily, titrate to max 400 mg/day; hepatotoxicity risk
• Cannabinoids (Nabiximols): Oromucosal spray; moderate evidence for spasticity reduction; not universally available

Interventional:

• Intrathecal Baclofen pump: For severe refractory spasticity
• Botulinum toxin injections: Focal spasticity (e.g., adductors)

Fatigue

Most common and disabling symptom (75-90% of patients)

Non-Pharmacological (First-Line):

• Energy conservation strategies, activity pacing
• Treatment of contributing factors: Depression, sleep disorders (sleep apnea, insomnia), deconditioning, anemia, hypothyroidism, medications (interferons)
• Exercise programs (aerobic and resistance training)
• Cooling strategies (for heat-sensitive fatigue)

Pharmacological:

• Amantadine: 100 mg BID; modest evidence
• Modafinil: 100-200 mg daily; mixed evidence, less studied than amantadine
• Stimulants: Methylphenidate (off-label, limited evidence)

Bladder Dysfunction

Assessment: Urodynamic testing differentiates:

• Detrusor hyperreflexia (urgency, frequency, urge incontinence): Most common
• Detrusor-sphincter dyssynergia (incomplete emptying, retention, UTIs)
• Mixed patterns

Detrusor Hyperreflexia:

• Anticholinergics: Oxybutynin, tolterodine, solifenacin
• β3-agonist: Mirabegron

Incomplete Emptying/Retention:

• Clean intermittent self-catheterization (CISC)
• α-blockers: Tamsulosin (relax bladder neck)

UTI Prevention:

• Adequate hydration
• Complete bladder emptying
• Cranberry supplements (limited evidence)
• Prophylactic antibiotics if recurrent

Neuropathic Pain

Trigeminal Neuralgia:

• Carbamazepine: First-line; 100-200 mg BID, titrate to effect (max 1200 mg/day)
• Oxcarbazepine, lamotrigine (alternatives)
• Surgical options for refractory cases: Microvascular decompression, gamma knife radiosurgery

Dysesthetic Limb Pain:

• Gabapentin: 300 mg TID, titrate to max 3600 mg/day
• Pregabalin: 75 mg BID, titrate to max 600 mg/day
• Tricyclic antidepressants: Amitriptyline 10-75 mg qhs
• SNRIs: Duloxetine 60 mg daily

Lhermitte's Sign:

• Usually resolves spontaneously
• Carbamazepine or gabapentin if persistent

Tremor and Ataxia

Challenging to Treat; Often Refractory

Pharmacological:

• Propranolol, primidone (limited efficacy)
• Ondansetron (modest benefit in small studies)
• Isoniazid (poor tolerability)

Non-Pharmacological:

• Weighted utensils, wrist weights
• Occupational therapy
• Functional electrical stimulation

Interventional:

• Deep brain stimulation (DBS) of thalamus (VIM nucleus): For severe refractory tremor, requires careful patient selection

Depression and Anxiety

Screening: PHQ-9, GAD-7 at diagnosis and annually

Management:

• SSRIs: Sertraline, escitalopram, citalopram (first-line)
• SNRIs: Venlafaxine, duloxetine
• Cognitive behavioral therapy (CBT)
• Mindfulness-based interventions
• Treat fatigue, pain, and other contributing symptoms [38]

---

9.4 Rehabilitation and Multidisciplinary Care

Core Principle: MS requires multidisciplinary team approach integrating neurologists, MS nurses, physiotherapists, occupational therapists, speech therapists, neuropsychologists, urologists, and social workers.

Physiotherapy:

• Gait training, balance exercises
• Spasticity management
• Fall prevention
• Aerobic and resistance exercise programs (shown to improve fatigue, mobility, quality of life)

Occupational Therapy:

• Activities of daily living (ADL) training
• Home modifications, assistive devices
• Energy conservation techniques
• Cognitive rehabilitation strategies

Speech and Language Therapy:

• Dysarthria assessment and management
• Swallowing assessment (dysphagia)
• Cognitive-communication interventions

Vocational Rehabilitation:

• Workplace accommodations
• Career counseling
• Disability benefits navigation

Psychological Support:

• Individual and group therapy
• Peer support groups
• Caregiver support

---

9.5 Pregnancy and MS

Effect of Pregnancy on MS:

• Relapse rate decreases during pregnancy (especially third trimester) by ~70%
• Postpartum period: 20-40% increase in relapse rate in first 3 months postpartum
• Overall disability: Pregnancy does not worsen long-term disability

DMT Management:

Before Conception:

• Stop teratogenic DMTs: Teriflunomide (washout with cholestyramine or activated charcoal required), cladribine (avoid pregnancy for 6 months after last dose)
• Stop most DMTs: Natalizumab, fingolimod, ocrelizumab, alemtuzumab
• Consider continuation: Glatiramer acetate, interferons (limited data but appear safe)

During Pregnancy:

• Most women discontinue DMTs (except glatiramer, interferons if needed)
• Extended interval Natalizumab (last dose in first trimester) may be considered in highly active disease
• Monitor clinically; MRI without gadolinium if relapse suspected

Postpartum Management:

• Resume DMT as soon as possible postpartum (balance breastfeeding considerations)
• Breastfeeding: Compatible with glatiramer, interferons; limited data for others
• Consider IV immunoglobulin (IVIG) postpartum to reduce relapse risk (some evidence)

Delivery:

• Vaginal delivery preferred (no increased risk)
• Epidural anesthesia safe (does not trigger relapses)
• Mode of delivery determined by obstetric indications [39]

---

10. Prognosis and Predictive Factors

Natural History (Untreated)

Historical natural history studies (pre-DMT era):

• Median time to requiring walking aid (EDSS 6.0): 15-20 years from onset
• Median time to wheelchair dependence (EDSS 7.0): 25-30 years
• Life expectancy reduced by 7-14 years compared to general population

Modern Era (DMT Treatment):

• Highly effective DMTs significantly delay disability progression
• NEDA (No Evidence of Disease Activity) achievable in 40-60% of patients on high-efficacy therapies
• Long-term disability outcomes substantially improved

Favorable Prognostic Factors

• Female sex (though higher incidence, better prognosis)
• Young age at onset (less than 30 years)
• Relapsing-remitting course (vs primary progressive)
• Purely sensory or optic neuritis as initial presentation
• Complete recovery from first relapse
• Long interval between first and second relapse (> 2 years)
• Low lesion burden on baseline MRI
• No spinal cord involvement
• Early initiation of high-efficacy DMT

Unfavorable Prognostic Factors

• Male sex
• Older age at onset (> 40 years)
• Primary progressive course
• Motor, cerebellar, or sphincter symptoms at onset
• Incomplete recovery from relapses
• High baseline lesion burden (> 10 T2 lesions)
• Spinal cord lesions
• Infratentorial lesions
• Frequent relapses in first 2 years (> 2 per year)
• Short interval to secondary progression (less than 5 years)
• Paramagnetic rim lesions (smoldering plaques) on MRI

Disability Scales

Expanded Disability Status Scale (EDSS):

• 0-10 scale (0.5 increments)
• 0: Normal neurological exam
• 4.0: Walks without aid, up and about 12 hours/day
• 6.0: Requires unilateral walking aid (cane)
• 7.0: Wheelchair-bound
• 10: Death due to MS
• Heavily weighted toward ambulation; less sensitive to cognitive, upper limb, fatigue changes

Multiple Sclerosis Functional Composite (MSFC):

• Quantitative measure combining:
  • Timed 25-Foot Walk (T25FW)
  • 9-Hole Peg Test (9HPT) - upper limb function
  • Paced Auditory Serial Addition Test (PASAT-3) - cognitive processing
• More sensitive to change than EDSS

Patient-Reported Outcome Measures:

• Multiple Sclerosis Impact Scale (MSIS-29)
• MS Quality of Life-54 (MSQoL-54) [40]

---

11. Emerging Therapies and Future Directions

BTK Inhibitors (Bruton's Tyrosine Kinase)

Mechanism: Inhibits BTK enzyme in B-cells and microglia/macrophages; dual effects on adaptive and innate immunity.

Agents in Development:

• Tolebrutinib: Phase III trials (HERCULES, GEMINI 1/2) completed; reduces disability progression in PPMS and SPMS
• Evobrutinib: Phase III trials ongoing
• Fenebrutinib: Phase III trials ongoing

Advantages:

• Oral daily dosing
• CNS penetration (targets compartmentalized inflammation)
• Potential benefit in progressive MS
• Less immunosuppression than B-cell depletion

Status: Likely to receive regulatory approval in 2026-2027 for SPMS/PPMS. [41]

Remyelination Therapies

Concept: Promote oligodendrocyte precursor cell (OPC) differentiation and myelin repair.

Agents:

• Opicinumab: Anti-LINGO-1 antibody (Phase II trials mixed results)
• Clemastine: Antihistamine with promyelinating properties (Phase II showed VEP improvement in chronic optic neuropathy)
• Metformin: Preclinical data suggests OPC differentiation
• Biotin (high-dose MD1003): Conflicting trial results; unclear benefit

Challenge: Chronic lesions have depleted OPC pools and inhibitory glial scar; remyelination therapies most likely to benefit acute/subacute lesions.

Neuroprotection

Simvastatin: Phase II trial (MS-STAT) showed reduction in brain atrophy in SPMS; Phase III ongoing.

Ibudilast: Phosphodiesterase inhibitor; SPRINT-MS trial showed reduced brain atrophy in progressive MS.

Lipoic Acid: Antioxidant; Phase II trial showed reduced brain atrophy.

Cellular Therapies

Autologous Hematopoietic Stem Cell Transplantation (aHSCT):

• Ablative chemotherapy followed by stem cell rescue
• "Immune reset"
• High efficacy (> 80% NEDA at 5 years in selected patients)
• Significant toxicity and mortality risk (~1-2% treatment-related mortality)
• Reserved for aggressive relapsing MS refractory to multiple DMTs
• Not recommended for progressive MS without inflammatory activity
• Performed at specialized centers with experience

Mesenchymal Stem Cells (MSCs):

• Preclinical and early clinical trials
• Immunomodulatory and neuroprotective properties
• Safety demonstrated; efficacy uncertain

Precision Medicine

Biomarker-Guided Therapy:

• Neurofilament light chain (NfL) monitoring for treatment decisions
• Genetic profiling for DMT response prediction
• MRI radiomics (quantitative lesion analysis, paramagnetic rim detection)

Microbiome Modulation:

• Gut microbiome alterations in MS
• Potential therapeutic target (probiotics, fecal microbiota transplant) - early research phase [42]

---

12. Key Clinical Pearls

Clinical Pearl: 1. Bilateral INO: Virtually pathognomonic of MS in young adults. "BINO = MS until proven otherwise."

2. Uhthoff's is not a relapse: Transient symptom worsening with heat does not require steroids; counsel patients on cooling strategies.

3. Delay in diagnosis costs neurons: The 2017 McDonald criteria allow earlier diagnosis (CSF OCBs substitute for DIT); early high-efficacy DMT initiation is critical.

4. JCV status is not binary: JCV antibody index > 1.5 confers higher PML risk on Natalizumab than index less than 0.9. Recheck every 6 months.

5. Not all white spots are MS: Middle-aged/elderly patients with vascular risk factors likely have small vessel disease. Look for optic nerve/spinal cord lesions, periventricular orientation, absence of vascular risk factors.

6. LETM (≥3 segments) is red flag: Consider NMOSD (AQP4-IgG), MOGAD (MOG-IgG), sarcoidosis, spinal dural AV fistula, NOT typical MS.

7. Fatigue is multifactorial: Before prescribing amantadine, screen for and treat depression, sleep disorders, deconditioning, thyroid dysfunction, anemia.

8. Post-Natalizumab switching requires caution: Risk of severe rebound disease activity. Bridge with oral DMT or short-interval switch to Ocrelizumab.

9. NEDA is the goal: No Evidence of Disease Activity (no relapses, no disability progression, no MRI activity) should be the therapeutic target, not just "reducing" relapses.

10. Pregnancy paradox: Pregnancy is protective (reduced relapses), but postpartum period is high-risk. Plan DMT resumption immediately after delivery.

---

13. Single Best Answer (SBA) Questions

Question 1

A 30-year-old female presents with double vision. On examination, when she looks to the right, the left eye fails to adduct past the midline, and the right eye exhibits horizontal nystagmus. Convergence is intact. What is the anatomical location of the lesion?

• A) Right Abducens Nerve
• B) Left Oculomotor Nerve
• C) Left Medial Longitudinal Fasciculus (MLF)
• D) Right Medial Longitudinal Fasciculus (MLF)
• E) Edinger-Westphal Nucleus

Answer: C.

Explanation: This is a classic presentation of Left Internuclear Ophthalmoplegia (INO). The MLF connects the contralateral CN VI nucleus to the ipsilateral CN III nucleus (medial rectus subnucleus). When the patient looks to the right (rightward gaze), the right CN VI nucleus activates, and signals travel via the right MLF to the left CN III nucleus. A lesion in the left MLF disrupts this pathway, causing failure of adduction of the left eye. The right eye abducts normally but exhibits nystagmus (compensatory). Intact convergence (near reflex) distinguishes INO from CN III palsy because convergence uses a separate pathway (not MLF-mediated).

---

Question 2

What is the molecular target of Natalizumab, and how does it prevent MS relapses?

• A) CD20 on B-cells
• B) IL-17 receptor
• C) α4β1 Integrin (VLA-4) on T-cells
• D) S1P receptor on lymphocytes
• E) Dihydroorotate dehydrogenase

Answer: C.

Explanation: Natalizumab is a humanized monoclonal antibody that binds to the α4 subunit of α4β1 integrin (VLA-4) on the surface of T-cells and other leukocytes. This integrin normally binds to VCAM-1 (vascular cell adhesion molecule-1) expressed on inflamed CNS endothelium, facilitating transmigration of autoreactive T-cells across the blood-brain barrier. By blocking this interaction, Natalizumab prevents immune cell entry into the CNS, thereby reducing inflammation and relapses. The AFFIRM trial demonstrated a 68% reduction in annualized relapse rate.

---

Question 3

A 35-year-old woman with RRMS has been on Natalizumab for 30 months. She is JCV antibody positive with an index of 2.1. She has had no relapses and MRI shows no new lesions. What is the most appropriate management regarding her DMT?

• A) Continue Natalizumab indefinitely as she is doing well
• B) Switch to Ocrelizumab due to PML risk
• C) Switch to Glatiramer Acetate to reduce PML risk
• D) Extend Natalizumab dosing interval to every 6 weeks
• E) Stop all DMTs given disease stability

Answer: B.

Explanation: This patient has high PML risk due to three factors: JCV antibody positive, high index (> 1.5), and duration > 2 years. Her risk is approximately 1:100, which is unacceptable. While option D (extended interval dosing every 5-6 weeks) reduces PML risk modestly, switching to a high-efficacy DMT without PML risk (Ocrelizumab, Ofatumumab) is the safest strategy. Option C (Glatiramer) is a lower-efficacy DMT and would represent de-escalation with risk of disease reactivation. Option E (stopping DMT) is inappropriate given her RRMS. Careful monitoring during transition is essential to avoid rebound activity.

---

Question 4

A 28-year-old man presents with 3 days of progressive ascending weakness and numbness starting in both feet, now involving the trunk up to the nipple line. He has urinary retention. MRI spine shows a T2 hyperintense lesion extending from T6 to T10 with central cord involvement and marked swelling. Which additional investigation is most likely to yield the diagnosis?

• A) CSF oligoclonal bands
• B) Serum aquaporin-4 (AQP4) antibodies
• C) Serum vitamin B12 level
• D) Lyme serology
• E) Genetic testing for adrenoleukodystrophy

Answer: B.

Explanation: This patient has longitudinally extensive transverse myelitis (LETM) defined as a spinal cord lesion extending ≥3 vertebral segments (T6-T10 = 5 segments). Additionally, the lesion is centrally located with marked swelling, which are features highly suggestive of Neuromyelitis Optica Spectrum Disorder (NMOSD). NMOSD is caused by antibodies against aquaporin-4 (AQP4-IgG), a water channel on astrocytes. LETM is atypical for MS, which usually causes short-segment (less than 3 segments), peripheral cord lesions. CSF oligoclonal bands (option A) are common in MS but less specific here. The clinical and radiological features strongly point toward NMOSD, making serum AQP4 antibody testing the highest yield investigation.

---

Question 5

Which of the following DMTs requires CYP2C9 genotyping before initiation?

• A) Ocrelizumab
• B) Fingolimod
• C) Siponimod
• D) Dimethyl fumarate
• E) Natalizumab

Answer: C.

Explanation: Siponimod is a selective S1P1 and S1P5 receptor modulator approved for active secondary progressive MS. It is metabolized primarily by CYP2C9 enzyme. Patients with **CYP2C93/3 genotype (poor metabolizers) have markedly reduced drug clearance, leading to potentially toxic drug accumulation. Therefore, CYP2C9 genotyping is mandatory before siponimod initiation, and the drug is contraindicated in CYP2C9*3/3 patients. Dose adjustment is required for CYP2C91/*3 and *2/*3 genotypes. This is unique among MS DMTs.

---

14. Viva Scenario: The "Normal MRI" Suspect

Examiner: "Your patient has a clinical history suggestive of two neurological episodes: optic neuritis 6 months ago and a sensory level episode 2 months ago. However, the MRI brain is completely normal. What is your next step?"

Candidate Response (Model Answer):

"Thank you for the question. This is a diagnostically challenging scenario where the clinical history suggests CNS demyelination with dissemination in time (two episodes separated by months) and space (optic nerve and spinal cord), but the brain MRI does not support the diagnosis."

Step 1: Imaging Gap Assessment "My first priority would be to order an MRI of the whole spinal cord (cervical and thoracic) with and without gadolinium. Up to 10-15% of MS patients may have a normal or near-normal brain MRI at initial presentation but harbor significant demyelinating lesions in the spinal cord. Given the patient's history of sensory level, a spinal cord lesion is highly likely."

Step 2: Alternative Demyelinating Diagnoses "The combination of optic neuritis and transverse myelitis should prompt consideration of other CNS demyelinating disorders beyond MS, particularly:

• NMOSD (Neuromyelitis Optica Spectrum Disorder): I would send serum aquaporin-4 (AQP4) IgG antibodies. NMOSD often has a normal or non-specific brain MRI, with pathology predominantly affecting the optic nerves and spinal cord. If the spinal MRI shows a longitudinally extensive lesion (≥3 vertebral segments) with central cord involvement, this would strongly support NMOSD.
• MOGAD (MOG Antibody-Associated Disease): I would also send serum MOG IgG antibodies (using a cell-based assay). MOGAD can present with recurrent optic neuritis and myelitis, and MRI findings can be less typical for MS."

Step 3: CSF Analysis "I would perform a lumbar puncture to look for:

• Oligoclonal bands: Present in > 95% of MS patients but less common in NMOSD (20-30%) and MOGAD (10-20%). CSF-specific oligoclonal bands would support MS and, per the 2017 McDonald criteria, can fulfill the dissemination in time criterion.
• CSF cell count and protein: Marked pleocytosis (> 50 cells) or very high protein would suggest alternative inflammatory or infectious processes.
• Exclusion of infection or malignancy."

Step 4: Evoked Potentials "I would consider visual evoked potentials (VEP) to objectively document optic nerve demyelination. A prolonged P100 latency would provide electrophysiological evidence supporting the clinical diagnosis of optic neuritis, even if optic nerve MRI is normal or was not performed."

Step 5: Exclude Mimics "I would also send basic blood work to exclude MS mimics:

• Vitamin B12 and copper (both can cause myelopathy and optic neuropathy)
• HIV, syphilis serology (infectious myelopathies)
• ANA, anti-dsDNA, complement levels (SLE can cause transverse myelitis)
• ACE level, serum calcium (neurosarcoidosis)
• If there is a history of travel or tick exposure, Lyme serology."

Examiner Follow-Up: "The spinal MRI shows a single short-segment T2 hyperintense lesion at C5-C6, peripherally located in the left dorsal column, with gadolinium enhancement. CSF shows oligoclonal bands. AQP4 and MOG antibodies are negative. What is your diagnosis and management?"

Candidate: "This patient now meets the 2017 McDonald criteria for MS. We have:

• Dissemination in space: Optic nerve lesion (clinical optic neuritis) and spinal cord lesion on MRI (two separate CNS locations).
• Dissemination in time: Two clinical episodes (optic neuritis and myelitis separated by months), and the presence of CSF oligoclonal bands, which can substitute for the DIT criterion per the 2017 revision.

The spinal lesion characteristics—short-segment (less than 3 vertebral segments), peripheral location, and enhancement—are typical for MS and not NMOSD or MOGAD.

Management:

1. Initiate disease-modifying therapy: Given the patient has clinically definite MS with two relapses in 6 months, I would recommend early high-efficacy therapy such as Ocrelizumab or Ofatumumab to reduce future relapse risk and disability progression.
2. Symptomatic management: Address any residual symptoms from the relapses.
3. Multidisciplinary care: Involve MS specialist nurse, physiotherapy, occupational therapy as needed.
4. Surveillance MRI: Baseline MRI and annual follow-up to monitor disease activity.
5. Patient education: Discuss diagnosis, prognosis, treatment options, lifestyle modifications (vitamin D supplementation, smoking cessation if applicable)."

Examiner: "Excellent. Why did you choose Ocrelizumab over Natalizumab despite similar efficacy?"

Candidate: "Both are highly effective, but there are several considerations:

• PML risk: Natalizumab carries a significant risk of progressive multifocal leukoencephalopathy (PML), particularly in JCV antibody-positive patients with prolonged exposure (> 2 years). Ocrelizumab has not shown PML risk in clinical trials (rare post-marketing cases in patients previously on Natalizumab).
• Convenience: Ocrelizumab is dosed every 6 months (infusions), while Natalizumab requires monthly infusions, which some patients find burdensome.
• Monitoring: Natalizumab requires JCV antibody testing every 6 months and frequent MRI surveillance for PML. Ocrelizumab monitoring is simpler (CBC, immunoglobulin levels annually).

However, if this patient had very aggressive disease (e.g., multiple severe relapses in short time, extensive brainstem lesions, poor recovery) and was JCV antibody negative, Natalizumab would be a reasonable choice given its rapid onset of action and extremely high efficacy (68% ARR reduction). The decision should be individualized based on disease activity, patient preference, and risk tolerance."

---

15. Patient Explanation

"Multiple Sclerosis is a condition where your immune system—which is supposed to protect you from infections—becomes confused and starts attacking the protective coating around the nerve fibers in your brain and spinal cord. This coating, called myelin, works like the insulation on an electrical wire. When it gets damaged, the nerve signals slow down or get blocked, which causes symptoms like numbness, vision problems, weakness, or difficulty with balance.

MS affects people differently. Some have episodes of symptoms (called relapses) followed by periods of recovery, while others have symptoms that gradually worsen over time. The good news is that we have very effective medications now that can dramatically reduce relapses and slow down the disease. These medications work by calming down the immune system so it stops attacking the myelin.

We'll monitor your condition with regular MRI scans to see if there's any new activity in your brain or spinal cord, and we'll work with a team—including physiotherapists, occupational therapists, and specialist nurses—to manage any symptoms and help you stay as active and independent as possible. Many people with MS live full, active lives for decades, especially with today's treatments started early."

---

16. References

1. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. [PMID: 29275977]

2. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816-1821. [PMID: 33174475]

3. Lucchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365(23):2188-2197. [PMID: 22150037]

4. Absinta M, Sati P, Schindler M, et al. Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. J Clin Invest. 2016;126(7):2597-2609. [PMID: 27270177]

5. Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. Am J Med. 2020;133(12):1380-1390.e2. [PMID: 32682870]

6. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777-788. [PMID: 29686116]

7. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007;61(4):288-299. [PMID: 17444504]

8. Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296-301. [PMID: 35025605]

9. Lanz TV, Brewer RC, Ho PP, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022;603(7900):321-327. [PMID: 35082464]

10. Voskuhl RR, Momtazee C. Pregnancy: Effect on Multiple Sclerosis, Treatment Considerations, and Breastfeeding. Neurotherapeutics. 2017;14(4):974-984. [PMID: 28726081]

11. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365(6460):eaav7188. [PMID: 31604244]

12. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683-747. [PMID: 15771584]

13. Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol. 2012;33(12):579-589. [PMID: 22926201]

14. Codarri L, Gyülvészi G, Tosevski V, et al. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol. 2011;12(6):560-567. [PMID: 21516112]

15. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221-234. [PMID: 28002679]

16. Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol. 2014;10(4):225-238. [PMID: 24638138]

17. Waxman SG. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat Rev Neurosci. 2006;7(12):932-941. [PMID: 17115075]

18. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14(2):183-193. [PMID: 25772897]

19. Frischer JM, Weigand SD, Guo Y, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78(5):710-721. [PMID: 26239536]

20. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8(11):987-997. [PMID: 19748319]

21. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998;64(3):402-404. [PMID: 9527164]

22. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209-220. [PMID: 28002688]

23. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992;326(9):581-588. [PMID: 1734247]

24. Morrow SA, Fraser JA, Day C, et al. Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial. JAMA Neurol. 2018;75(6):690-696. [PMID: 29582083]

25. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59(4):499-505. [PMID: 12236201]

26. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008;7(12):1139-1151. [PMID: 19007738]

27. Feinstein A, Magalhaes S, Richard JF, Audet B, Moore C. The link between multiple sclerosis and depression. Nat Rev Neurol. 2014;10(9):507-517. [PMID: 25112509]

28. Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009;72(9):800-805. [PMID: 19073949]

29. Petzold A, Balcer LJ, Calabresi PA, et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2017;16(10):797-812. [PMID: 28920886]

30. Kuhle J, Kropshofer H, Haering DA, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019;92(10):e1007-e1015. [PMID: 30709932]

31. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76(3):294-300. [PMID: 21242498]

32. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910. [PMID: 16510744]

33. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-1880. [PMID: 22591293]

34. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819-1828. [PMID: 23122652]

35. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416-426. [PMID: 20089954]

36. La Mantia L, Di Pietrantonj C, Rovaris M, et al. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2016;11(11):CD009333. [PMID: 27866562]

37. Hauser SL, Kappos L. Neurodegeneration and Neuroimmunology: Implications for the Future of MS Trials. Neurology. 2021;96(3):107-109. [PMID: 33310938]

38. NICE Guideline NG220. Multiple sclerosis in adults: management. National Institute for Health and Care Excellence. 2022. [www.nice.org.uk/guidance/ng220]

39. Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. Pract Neurol. 2019;19(2):106-114. [PMID: 30700537]

40. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452. [PMID: 6685237]

41. Reich DS, Arnold DL, Vermersch P, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021;20(9):729-738. [PMID: 34339647]

42. Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron. 2018;97(4):742-768. [PMID: 29470968]

---

Last Updated: 2026-01-06 | MedVellum Editorial Team